EUVIMEDEUVIMED entdecken
Open Access

Anemia and Blood Biomarkers of Alzheimer Disease in Dementia Development

Martina Valletta, Davide Liborio Vetrano, Chengxuan Qiu, Marco Canevelli, Edoardo Miccoli, Sarah Andersson, Claudia Fredolini, Giuseppe Bruno, Bengt Winblad, Laura Fratiglioni, Giulia Grande

JAMA Network Open · 2026

DOI: 10.1001/jamanetworkopen.2026.4029 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, 2026. Verfasst von Martina Valletta und 10 weiteren Autor:innen. Beteiligte Einrichtung: Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University, Stockholm, Sweden. Hauptthemen laut MEDLINE: Biomarkers, Alzheimer Disease, Anemia, Dementia. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Anemia has been associated with increased dementia risk, but its relationship with Alzheimer disease (AD) blood biomarkers remains unclear.

Objective

To investigate whether there is a cross-sectional association between hemoglobin and AD blood biomarker levels and a longitudinal association of hemoglobin and AD biomarkers with incident dementia. Design, Setting, and Participants This cohort study used data from the Swedish National Study on Aging and Care in Kungsholmen (SNAC-K), a longitudinal population-based study. Randomly selected adults aged 60 years or older were enrolled at baseline (March 21, 2001, to August 30, 2004) and followed up every 3 or 6 years according to age through December 31, 2019. Data analysis was conducted between September 1, 2024, and January 7, 2026. Exposures Hemoglobin level measured at baseline. Anemia was defined according to World Health Organization criteria. Main Outcomes and Measures Incident dementia, diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition ( DSM-IV ) criteria, and serum concentrations of phosphorylated tau 217 (p-tau217), neurofilament light chain (NfL), and glial fibrillary acidic protein (GFAP), measured using Simoa assays. Cox proportional hazards regression and quantile regression models were used to examine the association of hemoglobin with dementia risk and AD blood biomarkers. The joint association of hemoglobin and AD blood biomarkers with dementia development using Cox proportional hazards regression was also explored.

Results

A total of 3363 adults were enrolled in SNAC-K (73.3% participation rate). After excluding those with dementia or missing AD biomarkers or hemoglobin measures, 2282 dementia-free participants were included in the current study (median age, 72.2 [IQR, 60.8-81.1] years; 1406 [61.6%] female). During a mean (SD) follow-up of 9.3 (4.3) years, 362 participants (15.9%) developed dementia. Compared with individuals with a normal hemoglobin level, those with anemia had higher baseline levels of p-tau217 (β, 0.22; 95% CI, 0.15-0.30), NfL (β, 0.25; 95% CI, 0.19-0.31), and GFAP (β, 0.08; 95% CI, 0.03-0.12) and showed a higher risk of developing dementia (hazard ratio [HR], 1.66; 95% CI, 1.21-2.28) during follow-up. Participants with both anemia and high p-tau217, NfL, or GFAP had the highest hazard of dementia (eg, adjusted HR of 3.64 [95% CI, 2.39-5.56] among those with anemia and high NfL). Conclusions and Relevance In this cohort study of dementia-free older adults, anemia was associated cross-sectionally with higher levels of AD blood biomarkers and longitudinally with increased dementia risk. The highest dementia risk occurred when low hemoglobin and elevated AD biomarkers coexisted, suggesting a potential interplay between anemia and neuropathology in dementia development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BiomarkersAlzheimer DiseaseAnemiaDementiaHumansFemaleMaleSwedenAgedtau ProteinsLongitudinal StudiesGlial Fibrillary Acidic ProteinMiddle AgedCross-Sectional StudiesHemoglobinsNeurofilament ProteinsAged, 80 and overCohort Studies

Substanzen

Biomarkerstau ProteinsGlial Fibrillary Acidic ProteinHemoglobinsNeurofilament Proteinsneurofilament protein L

Autor:innen und Institutionen

  • Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University, Stockholm, Sweden.
  • Stockholm Gerontology Research Center, Stockholm, Sweden.
  • Department of Human Neuroscience, Sapienza University, Rome, Italy.
  • Affinity Proteomics Stockholm, Science for Life Laboratory, Department of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health (CBH), Royal Institute of Technology (KTH), Solna, Sweden.
  • Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna, Sweden.
  • Theme Inflammation and Aging, Karolinska University Hospital, Huddinge, Sweden.

Zitieren

APA

Valletta, M., Vetrano, D. L., Qiu, C., Canevelli, M., Miccoli, E., Andersson, S., Fredolini, C., Bruno, G., Winblad, B., Fratiglioni, L., & Grande, G. (2026). Anemia and Blood Biomarkers of Alzheimer Disease in Dementia Development. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2026.4029

Vancouver

Valletta M, Vetrano DL, Qiu C, Canevelli M, Miccoli E, Andersson S, et al. Anemia and Blood Biomarkers of Alzheimer Disease in Dementia Development. JAMA Network Open. 2026. doi:10.1001/jamanetworkopen.2026.4029

BibTeX
@article{Valletta2026,
  author = {Valletta, Martina and Vetrano, Davide Liborio and Qiu, Chengxuan and Canevelli, Marco and Miccoli, Edoardo and Andersson, Sarah and Fredolini, Claudia and Bruno, Giuseppe and Winblad, Bengt and Fratiglioni, Laura and Grande, Giulia},
  title = {Anemia and Blood Biomarkers of Alzheimer Disease in Dementia Development},
  journal = {JAMA Network Open},
  year = {2026},
  doi = {10.1001/jamanetworkopen.2026.4029}
}
Kostenlos starten →